Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Diseases of the Thyroid

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 22 articles:
HTML format
Text format



Single Articles


    August 2019
  1. SCHIFF BA, McMurphy AB, Jasser SA, Younes MN, et al
    Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer.
    Clin Cancer Res. 2019;25:4862.
    PubMed     Text format    


    June 2019
  2. KURZROCK R, Ball DW, Zahurak ML, Nelkin BD, et al
    The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
    Clin Cancer Res. 2019 Jun 11. pii: 1078-0432.CCR-18-1881.
    PubMed     Text format     Abstract available


    May 2019
  3. ROBB R, Yang L, Shen C, Wolfe A, et al
    Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF(V600E) Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair.
    Clin Cancer Res. 2019 May 16. pii: 1078-0432.CCR-18-3625.
    PubMed     Text format     Abstract available


    April 2019
  4. SINGH TD, Song J, Kim J, Chin J, et al
    A novel orally active inverse agonist of estrogen-related receptor gamma (ERRgamma), DN200434, a booster of NIS in anaplastic thyroid cancer.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3007.
    PubMed     Text format     Abstract available


  5. CHIAPPETTA G, Tallini G, De Biasio MC, Pentimalli F, et al
    Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases.
    Clin Cancer Res. 2019;25:2675.
    PubMed     Text format    


    February 2019
  6. LANDA I, Pozdeyev N, Korch C, Marlow LA, et al
    Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-18-2953.
    PubMed     Text format     Abstract available


    October 2018
  7. MITMAKER EJ, Tabah R, How J
    Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-2820.
    PubMed     Text format     Abstract available


  8. SONG YS, Kim MJ, Sun HJ, Kim HH, et al
    Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth.
    Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-0663.
    PubMed     Text format     Abstract available


    August 2018
  9. YIM JH, Choi AH, Li AX, Qin H, et al
    Identification of Tissue Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0841.
    PubMed     Text format     Abstract available


  10. PRETE A, Lo AS, Sadow PM, Bhasin SS, et al
    Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFbeta1 axis.
    Clin Cancer Res. 2018 Aug 3. pii: 1078-0432.CCR-18-0693.
    PubMed     Text format     Abstract available


    July 2018
  11. XU M, Casio M, Range DE, Sosa JA, et al
    Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-17-3705.
    PubMed     Text format     Abstract available


    April 2018
  12. THAKUR S, Daley B, Gaskins K, Vasko VV, et al
    Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-17-3167.
    PubMed     Text format     Abstract available


  13. POZDEYEV N, Gay L, Sokol ES, Hartmaier RJ, et al
    Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0373.
    PubMed     Text format     Abstract available


    January 2018
  14. HANNA GJ, Busaidy NL, Chau NG, Wirth LJ, et al
    Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2297.
    PubMed     Text format     Abstract available


    November 2017
  15. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Text format     Abstract available


    October 2017
  16. MIN IM, Shevlin E, Vedvyas Y, Zaman M, et al
    CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
    Clin Cancer Res. 2017 Oct 12. pii: clincanres.2008.2017.
    PubMed     Text format     Abstract available


    June 2017
  17. IBRAHIMPASIC T, Xu B, Landa I, Dogan S, et al
    Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence.
    Clin Cancer Res. 2017 Jun 20. pii: clincanres.1183.2017.
    PubMed     Text format     Abstract available


  18. KOTIAN S, Zhang L, Boufraqech M, Gaskins K, et al
    Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.1043.2017.
    PubMed     Text format     Abstract available


    October 2016
  19. GIBSON WJ, Ruan DT, Paulson VA, Barletta JA, et al
    Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer.
    Clin Cancer Res. 2016 Oct 17. pii: clincanres.2154.2016.
    PubMed     Text format     Abstract available


  20. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Text format     Abstract available


    September 2016
  21. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    October 2015
  22. FREEMAN-KELLER M, Kim Y, Cronin H, Richards A, et al
    Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Clin Cancer Res. 2015 Oct 7. pii: clincanres.1136.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: